MedImmune is an innovative leader among biotechnology companies. We leverage intellectual property and state-of-the-art technologies as we develop the biological products in our rich pipeline.
Research & Development
Discovery, research optimization, and process development are among the founding strengths of MedImmune. We’re committed to the development of new biologics that hold tremendous potential for patients around the globe.
Locations for MedImmune R&D facilities include:
- Gaithersburg, MD
Gaithersburg is home to MedImmune headquarters and is our primary location for biologics R&D activities in the US. It is also the location of AstraZeneca’s Specialty Products Group. The Gaithersburg campus is located in the Mid-Atlantic biotech hub and close to the National Institutes of Health.
- Mountain View, Santa Clara, and Hayward, CA
MedImmune’s California facilities support our biologics R&D pipeline and marketed products. These facilities also support pharmacology analytics (pharmacokinetics/pharmacodynamics) and clinical and non-clinical sample and data management for the entire MedImmune pipeline. Our California facilities have recently established an immunology and microbiology capability in support of our Infectious Disease portfolio. In addition, they currently lead the development of annual influenza vaccine strain development and perform testing for our FluMist/Fluenz/FluMist Quadrivalent products.
- Cambridge, UK
MedImmune occupies state-of-the-art facilities at Granta Park on the outskirts of Cambridge. Cambridge is at the center of the largest biotech and high-tech cluster in Europe, and our site has developed strong collaborative links with the local scientific community. Employing over 550 staff, the site is a major R&D hub supporting the research and early development of the biologics portfolio, contributing to all of the MedImmune therapy areas with particular strengths in Respiratory & Inflammation and Oncology. MedImmune Cambridge was formerly Cambridge Antibody Technology (CAT), who formed a strategic alliance with AstraZeneca in 2004, ahead of acquisition in 2006 and integration with MedImmune LLC in 2007 to form the biologics research and development arm of AstraZeneca. Three marketed products were invented in Cambridge (Humira, Benlysta, and Abthrax) through CAT’s historical collaborations with Abbott and HGS, respectively.
In 2008 MedImmune unveiled the Aaron Klug Building, a new research and development facility in the heart of the UK's Cambridge bioscience community. This 92,000-square-foot building, named after the winner of the 1982 Nobel Prize for Chemistry, consists of two state-of-the-art laboratories – expanding the capacity for the number of drugs that can be developed each year in our Cambridge location.
From commercial-scale manufacturing of our marketed products, to the production of clinical trial materials for our advancing pipeline of products, MedImmune is an industry leader in manufacturing monoclonal antibodies and live viral vaccines.
Locations for MedImmune manufacturing facilities include: